Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants (ValEAR)
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
Sponsor: Albert Park
This PHASE2 trial investigates CMV and Cmv Congenital and is currently ongoing. Albert Park leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE2
▶ Show 10 earlier versions
-
Jun 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Enrolling By Invitation → Recruiting · Phase: PHASE3 → PHASE2
-
May 2019 — Aug 2019 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2019 — May 2019 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2018 — Apr 2019 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jul 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE3
-
May 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Park
- Genentech, Inc.
- National Institute on Deafness and Other Communication Disorders (NIDCD)
For direct contact, visit the study record on ClinicalTrials.gov .